Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC

Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.